» Articles » PMID: 19633101

Selective Activation of PI3Kalpha/Akt/GSK-3beta Signalling and Cardiac Compensatory Hypertrophy During Recovery from Heart Failure

Overview
Publisher Wiley
Date 2009 Jul 28
PMID 19633101
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Activation of phosphoinositide-3 kinase (PI3K) is essential for cell growth, relating to adaptive and maladaptive cardiac hypertrophy. This longitudinal canine study was designed to investigate the role of PI3Kalpha and PI3Kgamma in cardiac remodelling during congestive heart failure (CHF) and cardiac recovery (CR).

Methods And Results: All dogs were surgically instrumented. Congestive heart failure was induced by cardiac pacing for 3-4 weeks and CR was allowed by terminating pacing for 5-6 weeks after induction of HF. Control dogs had sham surgery, but did not undergo pacing. Left ventricular (LV) contractile function was depressed in CHF and restored to 80-90% of the normal level in CR, with a 25% increase in LV weight. The expression of PI3Kgamma was increased four-fold in CHF, but returned to control levels in CR. In contrast, the expression of PI3Kalpha in CHF was not different from that in controls, but increased three-fold in CR and was accompanied by increases in phosphorylation of Akt (five-fold), GSK-3beta (five-fold), beta-catenin (three-fold), mTOR (two-fold), and P70S6K (two-fold).

Conclusion: Our results indicate that PI3K isoforms are regulated differently during the course of CHF/CR and that the selective activation of PI3Kalpha, through Akt, GSK-3beta, and mTOR signalling pathways, may be involved in the development of cardiac compensatory hypertrophy and functional restoration.

Citing Articles

Tripartite motif 27 promotes cardiac hypertrophy via PTEN/Akt/mTOR signal pathways.

Chen Y, Liu Z, Hu Z, Feng X, Zuo L Bioengineered. 2022; 13(4):8323-8333.

PMID: 35311628 PMC: 9208448. DOI: 10.1080/21655979.2022.2051814.


The Role of microRNAs in Heart Failure: A Systematic Review.

Peterlin A, Pocivavsek K, Petrovic D, Peterlin B Front Cardiovasc Med. 2020; 7:161.

PMID: 33195446 PMC: 7593250. DOI: 10.3389/fcvm.2020.00161.


Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN/AKT pathway.

Zhang M, Jiang Y, Guo X, Zhang B, Wu J, Sun J J Cell Mol Med. 2019; 23(11):7685-7698.

PMID: 31465630 PMC: 6815784. DOI: 10.1111/jcmm.14641.


miR-133: A Suppressor of Cardiac Remodeling?.

Li N, Zhou H, Tang Q Front Pharmacol. 2018; 9:903.

PMID: 30174600 PMC: 6107689. DOI: 10.3389/fphar.2018.00903.


WNT Signaling in Cardiac and Vascular Disease.

Foulquier S, Daskalopoulos E, Lluri G, Hermans K, Deb A, Blankesteijn W Pharmacol Rev. 2017; 70(1):68-141.

PMID: 29247129 PMC: 6040091. DOI: 10.1124/pr.117.013896.